Deletion of Beta-strand and Alpha-helix Secondary Structure in Normal Prion Protein Inhibits Formation of Its Protease-resistant Isoform

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 Oct 3

PMID 11581371

Citations 16

Authors

I Vorberg

K Chan

S A Priola

Affiliations

Soon will be listed here.

Abstract

A fundamental event in the pathogenesis of transmissible spongiform encephalopathies (TSE) is the conversion of a normal, proteinase K-sensitive, host-encoded protein, PrP-sen, into its protease-resistant isoform, PrP-res. During the formation of PrP-res, PrP-sen undergoes conformational changes that involve an increase of beta-sheet secondary structure. While previous studies in which PrP-sen deletion mutants were expressed in transgenic mice or scrapie-infected cell cultures have identified regions in PrP-sen that are important in the formation of PrP-res, the exact role of PrP-sen secondary structures in the conformational transition of PrP-sen to PrP-res has not yet been defined. We constructed PrP-sen mutants with deletions of the first beta-strand, the second beta-strand, or the first alpha-helix and tested whether these mutants could be converted to PrP-res in both scrapie-infected neuroblastoma cells (Sc(+)-MNB cells) and a cell-free conversion assay. Removal of the second beta-strand or the first alpha-helix significantly altered both processing and the cellular localization of PrP-sen, while deletion of the first beta-strand had no effect on these events. However, all of the mutants significantly inhibited the formation of PrP-res in Sc(+)-MNB cells and had a greatly reduced ability to form protease-resistant PrP in a cell-free assay system. Thus, our results demonstrate that deletion of the beta-strands and the first alpha-helix of PrP-sen can fundamentally affect PrP-res formation and/or PrP-sen processing.

Citing Articles

Cervid Prion Protein Polymorphisms: Role in Chronic Wasting Disease Pathogenesis.

Arifin M, Hannaoui S, Chang S, Thapa S, Schatzl H, Gilch S Int J Mol Sci. 2021; 22(5).

PMID: 33668798 PMC: 7956812. DOI: 10.3390/ijms22052271.

A stretch of residues within the protease-resistant core is not necessary for prion structure and infectivity.

Munoz-Montesino C, Sizun C, Moudjou M, Herzog L, Reine F, Igel-Egalon A Prion. 2017; 11(1):25-30.

PMID: 28281924 PMC: 5360129. DOI: 10.1080/19336896.2016.1274851.

Generating Bona Fide Mammalian Prions with Internal Deletions.

Munoz-Montesino C, Sizun C, Moudjou M, Herzog L, Reine F, Chapuis J J Virol. 2016; 90(15):6963-6975.

PMID: 27226369 PMC: 4944278. DOI: 10.1128/JVI.00555-16.

Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.

Coleman B, Harrison C, Guo B, Masters C, Barnham K, Lawson V J Virol. 2013; 88(5):2690-703.

PMID: 24352465 PMC: 3958101. DOI: 10.1128/JVI.02720-13.

Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein.

Taguchi Y, Mistica A, Kitamoto T, Schatzl H PLoS Pathog. 2013; 9(6):e1003466.

PMID: 23825952 PMC: 3694865. DOI: 10.1371/journal.ppat.1003466.

References

Chesebro B, Wehrly K, Caughey B, Nishio J, Ernst D, Race R . Foreign PrP expression and scrapie infection in tissue culture cell lines. Dev Biol Stand. 1993; 80:131-40. View

Priola S . Prion protein and species barriers in the transmissible spongiform encephalopathies. Biomed Pharmacother. 1999; 53(1):27-33. DOI: 10.1016/s0753-3322(99)80057-2. View

Caughey B, Raymond G, Kocisko D, Lansbury Jr P . Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol. 1997; 71(5):4107-10. PMC: 191566. DOI: 10.1128/JVI.71.5.4107-4110.1997. View

Stahl N, Prusiner S . Prions and prion proteins. FASEB J. 1991; 5(13):2799-807. DOI: 10.1096/fasebj.5.13.1916104. View

Rogers M, Yehiely F, Scott M, Prusiner S . Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells. Proc Natl Acad Sci U S A. 1993; 90(8):3182-6. PMC: 46263. DOI: 10.1073/pnas.90.8.3182. View

Lehmann S, Harris D . Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells. J Biol Chem. 1997; 272(34):21479-87. DOI: 10.1074/jbc.272.34.21479. View

Donne D, Viles J, Groth D, Mehlhorn I, James T, Cohen F . Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci U S A. 1998; 94(25):13452-7. PMC: 28326. DOI: 10.1073/pnas.94.25.13452. View

De Strooper B, Umans L, Van Leuven F, Van Den Berghe H . Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway. J Cell Biol. 1993; 121(2):295-304. PMC: 2200101. DOI: 10.1083/jcb.121.2.295. View

Taraboulos A, Raeber A, Borchelt D, Serban D, Prusiner S . Synthesis and trafficking of prion proteins in cultured cells. Mol Biol Cell. 1992; 3(8):851-63. PMC: 275644. DOI: 10.1091/mbc.3.8.851. View

10.

Farquhar C, Dickinson A . Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol. 1986; 67 ( Pt 3):463-73. DOI: 10.1099/0022-1317-67-3-463. View

11.

Priola S, Chesebro B . A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol. 1995; 69(12):7754-8. PMC: 189717. DOI: 10.1128/JVI.69.12.7754-7758.1995. View

12.

Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B . Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 1996; 15(6):1255-64. PMC: 450028. View

13.

Lopez Garcia F, Zahn R, Riek R, Wuthrich K . NMR structure of the bovine prion protein. Proc Natl Acad Sci U S A. 2000; 97(15):8334-9. PMC: 26948. DOI: 10.1073/pnas.97.15.8334. View

14.

Rudd P, Endo T, Colominas C, Groth D, Wheeler S, Harvey D . Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A. 1999; 96(23):13044-9. PMC: 23897. DOI: 10.1073/pnas.96.23.13044. View

15.

Prusiner S, Groth D, Bolton D, Kent S, HOOD L . Purification and structural studies of a major scrapie prion protein. Cell. 1984; 38(1):127-34. DOI: 10.1016/0092-8674(84)90533-6. View

16.

MEYER R, McKinley M, Bowman K, Braunfeld M, Barry R, Prusiner S . Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A. 1986; 83(8):2310-4. PMC: 323286. DOI: 10.1073/pnas.83.8.2310. View

17.

Kascsak R, Rubenstein R, Merz P, Fersko R, Carp R, Wisniewski H . Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 1987; 61(12):3688-93. PMC: 255980. DOI: 10.1128/JVI.61.12.3688-3693.1987. View

18.

Guilbert C, Ricard F, Smith J . Dynamic simulation of the mouse prion protein. Biopolymers. 2000; 54(6):406-15. DOI: 10.1002/1097-0282(200011)54:6<406::AID-BIP50>3.0.CO;2-6. View

19.

Muramoto T, Scott M, Cohen F, Prusiner S . Recombinant scrapie-like prion protein of 106 amino acids is soluble. Proc Natl Acad Sci U S A. 1996; 93(26):15457-62. PMC: 26426. DOI: 10.1073/pnas.93.26.15457. View

20.

Race R, Caughey B, Graham K, Ernst D, Chesebro B . Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol. 1988; 62(8):2845-9. PMC: 253720. DOI: 10.1128/JVI.62.8.2845-2849.1988. View